Biopharma Business Development & M&A: Solutions for Advancing Deals in Today's Economic Environment

While the biotech industry has seen record years of venture investment, crossover investments, and IPOs, we have recently seen a slowdown in these activities, and private companies are now seeking new avenues for raising capital within the challenging biotech financing environment. Now, more than ever, venture-backed biotechs are looking to Big Biopharma to step up BD partnerships (for non-dilutive capital) and M&A transactions (to exit). This panel will discuss the trickle-down effect of current macroeconomic drivers to capital markets as well as Big Pharma strategic plans and deal priorities/parameters to public/private biotech financing needs. By engaging executives who have engineered some of the biggest recent deals, we will evaluate a diversity of approaches and how this trickle-down effect is dictating changes in deal types, deal structures, and key terms.